Aligos Therapeutics ALGS
NASDAQ ALGS
$5.05 +0.02 (+0.40%)
As of: Oct 21, 2026 · 12:20 PM EDT

Aligos Therapeutics (ALGS) EBITDA Margin (2019 - 2026)

Updated

Aligos Therapeutics' EBITDA Margin was -939.33% in Q1 2026, up 5183.82 percentage points from -6123.15% a year earlier and up 11832.27 percentage points from the prior quarter.

Analysis

Aligos Therapeutics (ALGS) EBITDA Margin (2019 - 2026) Analysis & Trends

For FY2025, EBITDA Margin at Aligos Therapeutics came in at -3982.39%, down 1541.87 percentage points from FY2024.

  • EBITDA Margin has now declined for three consecutive years, with a four-year change of -1107.83 percentage points (FY2021 to FY2025).
  • In earlier years, EBITDA Margin was -2440.52% in FY2024 (-1513.90 pp), -926.61% in FY2023 (-241.53 pp), -685.08% in FY2022 (+2189.48 pp) and -2874.56% in FY2021.
  • The Q1 2026 figure marks the highest quarterly EBITDA Margin since Q3 2023.
  • Compared with a year earlier, EBITDA Margin was higher in two of the last eight quarters, with an average year-over-year change of -1711.11 percentage points.
  • The best year-over-year quarter for EBITDA Margin over five years was Q4 2022 (a gain of 9517.17 percentage points); the worst was Q4 2025 (a drop of 9415.82 percentage points).
  • Per Business Quant data, ALGS's EBITDA Margin in the three quarters before Q1 2026 was -12771.60% (Q4 2025), -3800.40% (Q3 2025) and -1892.95% (Q2 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,131.52 Bn 1,100.11 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 616.33 Bn 534.86 Bn 17.26 Bn 35.95%
3 AbbVie 500.08 Bn 473.19 Bn 12.70 Bn 49.01%
4 Merck 366.80 Bn 321.17 Bn 12.21 Bn 6.02%
5 Novartis Ag 297.92 Bn 261.91 Bn 11.24 Bn -
6 Astrazeneca 261.59 Bn 235.28 Bn 12.86 Bn 33.11%
7 Amgen 234.86 Bn 190.26 Bn 7.24 Bn 46.01%
8 Gilead Sciences 189.95 Bn 164.15 Bn 6.22 Bn -124.26%
9 Pfizer 169.63 Bn 116.28 Bn 10.94 Bn 39.16%
10 Aligos Therapeutics 52.68 Mn -275.73 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -939.33%
Dec 31, 2025 -12,771.60%
Sep 30, 2025 -3,800.40%
Jun 30, 2025 -1,892.95%
Mar 31, 2025 -6,123.15%
Dec 31, 2024 -3,355.78%
Sep 30, 2024 -1,586.48%
Jun 30, 2024 -2,461.26%
Mar 31, 2024 -3,133.43%
Dec 31, 2023 -1,274.12%
Sep 30, 2023 -871.45%
Jun 30, 2023 -436.45%
Mar 31, 2023 -906.62%
Dec 31, 2022 -626.97%
Sep 30, 2022 -449.29%
Jun 30, 2022 -535.96%
Mar 31, 2022 -1,355.78%
Dec 31, 2021 -10,144.14%
Sep 30, 2021 -2,099.41%
Jun 30, 2021 -1,861.81%
API Access

Aligos Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ALGS&period=max&api_key=YOUR_API_KEY